Effect of lonidamine on human malignant gliomas: Biochemical studies

Marco G. Paggi, Carmine M. Carapella, Maurizio Fanciulli, Carlo Del Carlo, Sergio Giorno, Gabriella Zupi, Bruno Silvestrini, Antonio Caputo, Aristide Floridi

Research output: Contribution to journalArticle


Lonidamine (LND) has been shown to inhibit tumor aerobic glycolysis. Its effect was evaluated on several human astrocytomas at different degrees of malignancy; a correlation was found between LDN effect on lactate production and tumor malignancy: in grade I and II astrocytomas LND stimulates lactate production, while in grade III, IV and glioblastoma multiforme lactate production is inhibited. In an attempt to explain this different behaviour, hexokinase content and compartmentation was evaluated in astrocytomas from fresh operatory specimens and from cultured cells as well, observing a significative correlation between malignancy, hexokinase activity, percent of mitochondrially-bound hexokinase and LND effect. The results justify from a biochemical point of view the role of LND as a 'non-conventional' agent in multimodality combined treatment for malignant gliomas.

Original languageEnglish
Pages (from-to)203-209
Number of pages7
JournalJournal of Neuro-Oncology
Issue number3
Publication statusPublished - Nov 1988


  • astrocytoma
  • glycolysis
  • hexokinase
  • Lonidamine

ASJC Scopus subject areas

  • Neuroscience(all)
  • Oncology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'Effect of lonidamine on human malignant gliomas: Biochemical studies'. Together they form a unique fingerprint.

  • Cite this